Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966906534> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W1966906534 endingPage "186" @default.
- W1966906534 startingPage "180" @default.
- W1966906534 abstract "Therapeutic strategies based on the insertion of cytokine or other immunostimulatory genes into the genome of tumour cells followed by vaccination with the resulting, genetically modified, cytokine-producing vaccines represent a new potential prospect for the treatment of cancer patients. HPV 16 is the aetiological agent of more than 60 percent human cervical carcinomas (CC). At present, two prophylactic vaccines against HPV 16 are available (GlaxoSmithKline “Cervarix” and Merck “Gardasil”). These vaccines can almost completely protect the immunized individuals against both, persistent HPV 16 infection and HPV 16-related pathological findings in cervical cytology. In contrast, no clinically utilizable therapeutic vaccines against CC are available. During the last decade animal models have substantially contributed to the development of the therapeutic vaccines against HPV 16-associated tumours. It has been demonstrated that the HPV 16 E6/E7 oncoproteins can serve as tumour rejection antigens (TRA) and that the HPV 16-associated tumour cells can be genetically modified with DNA encoding immunostimulatory cytokines (IL-2, IL-12, GM-CSF) or other immunostimulatory molecules, used for vaccination, and inhibit tumour growth. To improve the HPV 16 antigen presentation in tumour-bearing individuals, dendritic cell-based vaccines loaded with HPV 16 E6/E7 DNA or hybrids of the dendritic and tumour cells have also been successfully employed. Unfortunately, when these encouraging approaches used in animal models were translated into clinical trials, the results were less optimistic. The problems that are still to be faced before the therapeutic vaccines against high-risk HPV-associated tumours can be approved for clinical purposes are discussed. Keywords: HPV 16, genetically modified vaccines" @default.
- W1966906534 created "2016-06-24" @default.
- W1966906534 creator A5081464065 @default.
- W1966906534 date "2008-05-01" @default.
- W1966906534 modified "2023-10-17" @default.
- W1966906534 title "Genetically Modified Cellular Vaccines for Therapy of Human Papilloma Virus Type 16 (HPV 16)-Associated Tumours" @default.
- W1966906534 doi "https://doi.org/10.2174/156800908784293596" @default.
- W1966906534 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18473731" @default.
- W1966906534 hasPublicationYear "2008" @default.
- W1966906534 type Work @default.
- W1966906534 sameAs 1966906534 @default.
- W1966906534 citedByCount "11" @default.
- W1966906534 countsByYear W19669065342012 @default.
- W1966906534 countsByYear W19669065342016 @default.
- W1966906534 countsByYear W19669065342018 @default.
- W1966906534 crossrefType "journal-article" @default.
- W1966906534 hasAuthorship W1966906534A5081464065 @default.
- W1966906534 hasConcept C104317684 @default.
- W1966906534 hasConcept C111599444 @default.
- W1966906534 hasConcept C121608353 @default.
- W1966906534 hasConcept C126322002 @default.
- W1966906534 hasConcept C147483822 @default.
- W1966906534 hasConcept C159047783 @default.
- W1966906534 hasConcept C167508917 @default.
- W1966906534 hasConcept C203014093 @default.
- W1966906534 hasConcept C22070199 @default.
- W1966906534 hasConcept C2777701055 @default.
- W1966906534 hasConcept C2778220009 @default.
- W1966906534 hasConcept C2778580637 @default.
- W1966906534 hasConcept C2780009117 @default.
- W1966906534 hasConcept C2780801004 @default.
- W1966906534 hasConcept C502942594 @default.
- W1966906534 hasConcept C55493867 @default.
- W1966906534 hasConcept C71924100 @default.
- W1966906534 hasConcept C86803240 @default.
- W1966906534 hasConcept C8891405 @default.
- W1966906534 hasConceptScore W1966906534C104317684 @default.
- W1966906534 hasConceptScore W1966906534C111599444 @default.
- W1966906534 hasConceptScore W1966906534C121608353 @default.
- W1966906534 hasConceptScore W1966906534C126322002 @default.
- W1966906534 hasConceptScore W1966906534C147483822 @default.
- W1966906534 hasConceptScore W1966906534C159047783 @default.
- W1966906534 hasConceptScore W1966906534C167508917 @default.
- W1966906534 hasConceptScore W1966906534C203014093 @default.
- W1966906534 hasConceptScore W1966906534C22070199 @default.
- W1966906534 hasConceptScore W1966906534C2777701055 @default.
- W1966906534 hasConceptScore W1966906534C2778220009 @default.
- W1966906534 hasConceptScore W1966906534C2778580637 @default.
- W1966906534 hasConceptScore W1966906534C2780009117 @default.
- W1966906534 hasConceptScore W1966906534C2780801004 @default.
- W1966906534 hasConceptScore W1966906534C502942594 @default.
- W1966906534 hasConceptScore W1966906534C55493867 @default.
- W1966906534 hasConceptScore W1966906534C71924100 @default.
- W1966906534 hasConceptScore W1966906534C86803240 @default.
- W1966906534 hasConceptScore W1966906534C8891405 @default.
- W1966906534 hasIssue "3" @default.
- W1966906534 hasLocation W19669065341 @default.
- W1966906534 hasLocation W19669065342 @default.
- W1966906534 hasOpenAccess W1966906534 @default.
- W1966906534 hasPrimaryLocation W19669065341 @default.
- W1966906534 hasRelatedWork W1120554102 @default.
- W1966906534 hasRelatedWork W1645539021 @default.
- W1966906534 hasRelatedWork W2026037372 @default.
- W1966906534 hasRelatedWork W2330155927 @default.
- W1966906534 hasRelatedWork W2588834344 @default.
- W1966906534 hasRelatedWork W2884792105 @default.
- W1966906534 hasRelatedWork W2911790415 @default.
- W1966906534 hasRelatedWork W3044185776 @default.
- W1966906534 hasRelatedWork W3100975367 @default.
- W1966906534 hasRelatedWork W3206509028 @default.
- W1966906534 hasVolume "8" @default.
- W1966906534 isParatext "false" @default.
- W1966906534 isRetracted "false" @default.
- W1966906534 magId "1966906534" @default.
- W1966906534 workType "article" @default.